Ninety-nine consecutive patients with acute leukemia in first complete remission under age 50 (median age 27 years; age range 1 to 4 7 years) with a histocompatible sibling donor were treated with fractionated total body irradiation (1,320 cGy) and high-dose etoposide (60 mg/kg) followed by allogeneic bone marrow transplantation. Sixty-one patients were diagnosed with acute myelogenous leukemia (AML), 34 patients with acute lymphoblastic leukemia (ALL), 3 patients with biphenotypic acute leukemia, and 1 patient with acute undifferentiated leukemia. Thirty of the 34 patients with ALL had at least one of the following high-risk factors: age greater than 30, white blood cell count at presentation > 25,OOO/pL, extramedullary disease, certain chromosomal translocations, or the need for greater than 4 weeks of induction chemotherapy OMPLETE REMISSION (CR) rates of 60% to 90% for
probability of continued CR at 5 years may be as low as 0%
Patients with AML and high-risk ALL have been treated with various combinations of high-dose radiochemotherapy followed by allogeneic bone marrow transplantation (BMT) in an effort to improve long-term DFS.19740 Patients with acute leukemia benefit the most from BMT when they are transplanted early in the course of their disease; that is, during first CR.
We have developed a novel preparatory regimen for the treatment of hematologic malignancies that consists of fractionated total body irradiation (FTBI) followed by highdose etoposide (VP-16) at 60 mg/kg of actual body weight. In a study using this regimen in 33 patients transplanted for acute leukemia beyond first CR, we reported a DFS rate of 43% and relapse rate of 32%. 41 These results were confirmed in a separate This regimen of FTBI/VP-16 was recently compared with busulfan/cyclophosphamide in a prospective, randomized Southwest Oncology Group study for BMT in patients with recurrent leukemia. 43 The estimated DFS for patients prepared with this regimen was 55% f 11% for "good-risk" patients (in second CR of acute leukemia or in accelerated phase of chronic myelogenous leukemia) and 17% f 6% for "poor-risk" patients (more advanced stages of leukemia). The incidence of relapse for these two groups of patients was 24 of 6 1 (39%). Encouraged by these relatively low relapse rates in patients with advanced disease, we have recently evaluated the efficacy of this preparatory regimen for patients with acute leukemia in first CR. Nineteen patients with high-risk ALL prepared with this FTBI/VP-16 regimen were included in an earlier report of 53 patients who were prepared with a variety of regimens before BMT with an overall DFS rate of 6 I %.' * At the time of that report none of these 19 patients had relapsed, although median follow-up was only 2 1 months. Seventeen of the 19 ALL patients with to 28y0.9-l 1,1618 ALL referred to in the previous study" are included in this report, which extends their follow-up to a median of 33 months.
We now report the results for 99 patients with acute leukemia in first CR prepared for BMT with the FTBI/VP- 16 regimen.
PATIENTS AND METHODS
Patients. Between September 1986 and April 1992,99 consecutive patients with acute leukemia in first CR were prepared for BMT using the FTBI/VP-16 regimen, including 6 1 with AML, 34 with ALL, 3 with biphenotypic acute leukemia, and one with acute undifferentiated leukemia. Date of analysis was September 30, 1992, with a minimum follow-up of 5 months for patients surviving to the date of analysis; 19 patients died between 19 days and 134 days after BMT.
The demographic data and disease characteristics for the 6 1 patients with AML are shown in Tables l and 2, including age and sex distribution, FAB subtype (Ml/M2, 27 patients, M3, 6 patients, and M4/M5, 19 patients), presenting WBC, cytogenetics data, the time from diagnosis (Dx) to CR, whether or not high-dose cytosine arabinoside (Ara-C) was used for remission induction before BMT, and the time from CR to BMT (median of 2.3 months).
Cytogenetics data were classified as low risk if either translocation t(8;21), t(15;17), or an abnormality of chromosome 16 was present; and high risk if either Ph+, trisomy 8, or monosomy 7 was present. Any other karyotype, including a normal pattern, was classified as intermediate
The majority of patients were referred to us for BMT after they had received their induction chemotherapy, and thus there was variability in the regimens used. Twenty-eight ofthe patients with AML received high-dose Ara-C and daunomycin for remission induction!' The rest were treated with standard-dose Ara-C in combination with daunomycin with or without 6-thioguanine.
The data for the 34 patients with ALL are given in Tables 1 and 3 . Seventeen of these 34 patients were included in a previous report from our group on 53 patients with high-risk ALL transplanted in first CR.*' The current report extends the median follow-up for those 17 patients by 12 months. Thirty of the 34 patients had one or more high-risk factors, which included age greater than 30 (n = 15); presenting WBC >25,OOO/pL (n = 2 1); extramedullary disease (n = 6); the chromosomal translocations t(4;Il) (n = I), t(8;14) (n = I), t(9;22), that is, Ph' (n = 4), or other translocations (n = 3); and the need for induction chemotherapy for more than 4 weeks to achieve a CR (n = 11). Of the 32 patients for whom immunophenotyping data were available, 5 patients had T-cell ALL, 24 had pre-B ALL, and 3 had B-cell ALL. The majority ofpatients were treated at other hospitals with various induction regimens, which included combinations of vincristine, prednisone, daunomycin, and L-asparaginase.
Three patients were diagnosed with biphenotypic acute leukemia based on the expression of both lymphoid and myeloid markers by the leukemic blasts. One patient, whose blasts expressed no specific surface or cytochemical markers, was classified as acute undifferentiated leukemia. These four patients are grouped as "Other" in Table l .
Preparatory regimen. All patients were treated with a uniform preparatory regimen consisting of ITBI, 1,320 cGy, in 1 1 fractions on day -7 through day -4;' and 60 mg/kg of VP-16, based on actual body weight, intravenously (IV) over 4 hours on day -3 as previously
The BM was collected from an HLA genotypically identical sibling donor and infused on day 0 without manipulation other than removal of red blood cells or plasma in cases of major or minor AB0 mismatch, respectively.
Graft-versus-host disease (GVHD) prophylaxis. Patients entered on this study between December 1986 and December 1991 were also included on a randomized, prospective study of GVHD prophylaxis that compared a two-drug regimen of cyclosporine and methylprednisolone with a three-drug regimen consisting of the same schedule of cyclosporine and methylprednisolone plus three doses of methotrexate. The details and results of this randomized study were recently p u b l i~h e d .~~~~~
Patients transplanted before December 1986 routinely received the two-drug regimen, whereas patients transplanted after December 199 l received the three-drug regimen ( Table 1) .
The schema for GVHD prophylaxis was as follows: All patients received cyclosporine 5 mg/kg/d by continuous IV infusion as a loading dose starting on day -2. The dose was reduced to 3 mg/kg/d on day +4, and increased to 3.75 mg/kg/d from day + I5 to day +35. Thereafter, patients received 5 mg/kg of oral cyclosporine twice a day until day +83, followed by a tapering dose until day + 180. Methotrexate was administered IV at a dose of 15 mg/m' on day t 1 and 10 mg/m' on days +3 and +6. Methylprednisolone was begun on day +7 at 0.25 mg/kg IV twice a day and doubled to 0.5 mg/kg IV twice a day on day + 15. At the time of discharge, the patients were switched to oral prednisone, which was then slowly tapered from day +29 until day +180.
All patients were housed in single rooms with a high-efficiency particulate air filtration system. Gut decontamination was accomplished with oral nonabsorbable antibiotics (neomycin and vancomycin), oral trimethoprim-sulfamethoxazole, and a strict, low-bacteria diet all starting approximately on day -8. Reverse isolation techniques with masks and gowns were used when neutrophil counts fell below 500/pL. Broad-spectrum antibiotics were used for the first febrile episode, and all patients received prophylactic low-dose amphotericin (0.15 mg/kg) starting on day + 1 . 51 All blood products were irradiated with 2,500 cGy before infusion. Intravenous Ig (Gammagard; Baxter Health Care Corp, Hyland Division, Glendale, CA, or Gamimune-N; Miles Inc, Cutter Biologicals, Elkhart, IN) was administered at a dose of 500 mg/kg every other week from day -7 to day +lo0 to all patients. Patients who were seropositive for cytomegalovirus (CMV) or who received a BM graft from a CMV-seropositive donor underwent bronchoalveolar lavage (BAL) on day +35. Those whose BAL specimens were positive for CMV received prophylactic gancyclovir as previously described by our group." None of the patients enrolled on this study were given hematopoietic growth factors.
Informed consent. All clinical protocols were approved by the Institutional Review Boards at City of Hope National Medical Center and Stanford University Medical Center. The risks and benefits were explained to each patient in detail both during outpatient visits and on the day of admission. Written consent was then obtained from the patient or from a parent or guardian for minor patients.
Factors associated with overall (OS) and disease-free survival (DFS) were examined by univariate Cox regression analy~is.'~ The risk ratio was calculated for each variable tested along with the 95% confidence interval. Stepwise Cox regression was performed to determine independent predictors of relapse and survival; all variables with P < .IO on univariate analysis were included as candidates in the analysis. Survival estimates were calculated based on the product-limit method,54 and 95% confidence intervals were calculated using the logit transformation and the Greenwood variance estimate. The Wilcoxon rank-sum test was used in comparing medians for continuous data, and Pearson's chisquare test was used to compare the incidence of GVHD between treatment regimens.
Statistical methods.

RESULTS
Engraftment.
Engraftment data were available for 98 of the 99 patients. One patient died at day 19 after BMT as a result of fungal infection before engraftment. For this group of 98 patients, all engrafted successfully with recovery of 2500 granulocytes/pL at a median of 13 days (range of 8 to 18 days) for patients receiving cyclosporine and prednisone and 19 days (range of I2 to 33 days) ( P < .OOO 1) for patients receiving the methotrexate regimen. The median time to recovery of r25,000 platelets/pL was 16 days (range of 1 to 124 days) for patients receiving cyclosporine and prednisone and 24 days (range of 3 to 139 days) (P = .001) for patients receiving the methotrexate regimen. Five patients in the two-drug arm required continuous platelet transfusion support, as did eight in the three-drug arm.
The toxicity of the preparative regimen consisted primarily of gastrointestinal mucositis and skin inflammation as we described previou~ly.~' Although these toxicities were a source of considerable morbidity (eg, the majority of patients required continuous infusions of narcotics for pain control during the first 2 weeks following BMT), only one patient died from toxicity during the first few weeks after BMT.
The three-year cumulative probability of DFS and OS for the 6 1 patients transplanted with AML in first CR was 61% (95% confidence interval [CI] of 48% to 73%), and the probability of relapse was 12% (95% CI of 5% to 24%) ( Fig I) . The 3-year probabilities of DFS/OS and relapse for the 18 patients <20 years ofage were 83% (95% CI of 57% to 94%) and 6% (95% CI of I% to 32%), respectively; and for the 43 patients 220 years ofage the probabilities were 52% (95% CI of 37% to 67%) and 15% (95% CI of Toxicity.
AML patients.
For personal use only. on January 4, 2018. by guest www.bloodjournal.org From 6% to 31%). The difference in probabilities of DFS/OS between these two groups was significant by log-rank test with P = .03, whereas the difference in probabilities of relapse was not significant.
For all patients, follow-up ranged from 1 to 73 months, with a median of 17 months. For patients surviving to the date of analysis, follow-up ranged from 7 to 73 months, with a median of 36 months. At the time of this analysis, 38 patients (62%) were alive in continued CR, 6 ( 10%) had died from relapsed leukemia, and 17 (28%) had died from other causes while in CR. All six relapses occured within the first year after BMT. The causes of death are listed in Table 4 . Death from complications related to acute or chronic GVHD ( 1 1 patients) was the major cause followed by re- or more (P = ,0007 for OS; P = .0008 for DFS). Variables found not to be significant included FAB subtype, presenting WBC at time of diagnosis, cytogenetics, whether or not patients received high-dose ARAC for remission induction, time from Dx to CR, time from CR to BMT, and CMV-IP.
Five patients with M4 AML associated with an inversion of chromosome 16 were grouped with the rest of the patients with M4jM5 AML, because their risk of survival was not different from that of the larger group. One of these five patients died from complications of chronic GVHD at 19.6 months after BMT; the other four patients are alive and free of disease at 13.4, 17.1, 37.3, and 38.2 months after BMT.
The 49 patients who survived in remission to day 100 were analyzed to assess whether chronic GVHD had any influence on relapse rates. For the 25 patients who did not develop chronic GVHD, the probability ofrelapse at 3 years was 16% (95% CI of 6% to 36%), whereas the probability of relapse at 3 years for the 24 patients who did develop chronic GVHD was 0. This difference was significant by log-rank test with P = .0465. The 3-year cumulative probability of DFS for the 34 patients transplanted with ALL in first CR was 64% (95% CI of 45% to 79%), and the probability of relapse was 12% (95% CI of 3% to 37%) (Fig 2) . The 3-year probabilities of DFS and relapse for the 7 patients <20 years of age were 100% and 0%, respectively; and for the 27 patients 220 years ofage the probabilities were 54% (95% CI of 34% to 73%) and 17% (95% CI of 4% to 49%). The difference in probabilities of DFS between these two groups was significant by log-rank test with P = .05, whereas the difference in probabilities of relapse was not significant.
ALL patients.
For all patients, follow-up ranged from 1 to 59 months, with a median of 24 months. For patients surviving to the date ofanalysis, follow-up ranged from 5 to 59 months, with a median of 28 months. At the time of this analysis, 22 patients (65%) were alive in continued CR, 2 (6%) had died from relapsed leukemia, and IO (29%) had died from other causes while in CR. There have been no relapses later than 25 months after BMT. The causes of death are listed in Table 4 . Two patients died from complications of chronic GVHD, two from organ failure, and six from a variety of other causes. Of the four patients with Ph+ ALL, two died from causes other than relapse at 2.2 and 2.7 months after BMT, and two patients were alive and free of disease at 5.3 and 56.8 months after BMT.
Univariate and multivariate stepwise Cox proportional hazard analyses of patient characteristics were performed to determine risk factors for overall OS and DFS, as shown in Table 3 . In the univariate analysis, CMV-IP was significant (P = .03 for OS and P = .O 1 for DFS), and age as a continuous variable just reached significance ( P = .05 for OS, P = .06 for DFS). In the multivariate stepwise model, the only significant risk for shortened OS was age at BMT (P = .04), and for DFS it was the development of CMV-IP (P = .03).
Variables found not to be significant by multivanate analysis included immunophenotype, presenting WBC, cytogenetics. extramedullary disease, time from Dx to CR, the total number of high-risk factors, time from CR to BMT, and acute or chronic GVHD. There was no difference in the probability of relapse at 3 years for the 15 patients who survived in remission to day 100 and did not develop chronic GVHD as compared with the 13 patients who did.
Other patients. At the time of this analysis, one patient with biphenotypic acute leukemia was alive in continued CR at 5.3 months after BMT, and the one patient with acute undifferentiated leukemia was alive in continued CR at 9.2 months after BMT. Two patients with biphenotypic acute leukemia died from relapsed leukemia; one relapsed at 2.5 months and died at 5.9 months, and the other relapsed at 5.9 months and died at 10.6 months after BMT.
Of the 99 patients in this study, 16% developed acute GVHD of grade I1 or more; for those patients who survived at least 100 days (82 patients), 48% developed some degree of chronic GVHD. The Karnofsky performance status (KPS) for the 62 patients alive at the time of this analysis ranged from 60 to 100, with 54 of the 62 patients (87%) at KPS of 90 or 100 ( Table 5 ).
Eighty of these 99 patients were included in the prospective, randomized study comparing cyclosporine/prednisone with cyclosporine/methotrexate/prednisone involving 1 50 patients recently reported by our group." In that study, the incidence of significant acute GVHD was 23% for patients who were randomized to the two-drug regimen and 9% ( P = .02) for those who were randomized to receive three drugs. The incidence of chronic GVHD was 60% in the two-drug arm and 57% in the three-drug arm of the study (P = .68).
For the 98 evaluable patients in the current study (both randomly and nonrandomly assigned to the two-drug arm [n = 5 11 or three-drug arm [n = 471 based on date of transplant), the incidence of grade I1 or greater acute GVHD was GVHD.
For personal use only. on January 4, 2018. by guest www.bloodjournal.org From 22% for the two-drug arm and 11% for the three-drug arm ( P = .14). The incidence of chronic GVHD among the 82 evaluable patients surviving to day 100 was 53% in the twodrug arm and 41% in the three-drug arm ( P = .26).
DISCUSSION
This study demonstrates the efficacy of the preparative regimen consisting of FTBI and high-dose VP-16 for patients with acute leukemia in first CR undergoing allogeneic BMT. Probabilities of DFS at 3 years were 6 1 % and 64%, respectively, for patients with AML and ALL, with relapse rates of 12% for both groups. These results compare favorably with previously published studies of BMT for first-remission leukemia patients.21~23~26,28.29,55 Patients underwent BMT relatively quickly following the achievement of CR, with median times from CR to BMT of 2.3 and 2.9 months, respectively, for patients with AML and ALL. Only two patients in each group were transplanted between 6 and 7 months after CR. The median ages of the two groups were 26.3 and 27.8 years, respectively, for patients with AML and ALL. There were 13 patients 40 years of age or older in the two groups.
All patients under age 50 with AML in first CR who were either referred to or treated at our institutions were considered to be candidates for BMT regardless of whether they had any favorable features such as M3 subtype or certain cytogenetic findings such as t( 15; 17) or t(8;2 1) ! 6 In fact, by Cox regression analysis, none of the pre-BMT disease characteristics, including FAB subtype, cytogenetics, presenting Most of the patients with ALL (30 of 34) had at least one of the traditional high-risk features associated with poor outcome with chemotherapy al~ne."~'"'~ By the Cox regression analysis, these high-risk features (other than age) had no significant impact on OS or DFS for the patients with ALL treated with this BMT regimen. The only significant variable for DFS was the development of CMV-IP and for OS it was age. In contrast to the analysis of risk factors for the patients with AML, the development of acute GVHD was not a significant risk for the patients with ALL. There was no significant improvement in outcome for patients with T-cell ALL versus pre-B ALL, nor was there a significantly adverse effect on outcome for patients with Ph+ ALL.
As discussed earlier, long-term DFS for patients with ALL who have none of the traditional high-risk factors is only 35% to 60% when treated with intensive chemotherapy. For patients with ALL with any one of these risk factors, DFS decreases to approximately 20% or l e~s .~-" . '~-'~ Our result of 64% 3-year DFS for this group of mostly highrisk patients with ALL (54% for patients 220 years of age) has encouraged us to postulate that there may be a role for BMT in improving DFS for any adult patient with ALL whether or not they have any of the traditional high-risk features. To test this hypothesis, we have initiated a pilot study in which any adult (2 18 years of age) with the diagnosis of ALL is treated with an intensive two-phase induction regimen. For those patients who achieve a CR, they are then assigned to allogeneic BMT if they have a histocompatible sibling available, and if not, they continue on with intensive consolidation chemotherapy followed by maintenance chemotherapy. The results of such a study will help define the For personal use only. on January 4, 2018. by guest www.bloodjournal.org From role of allogeneic BMT in the treatment of adult patients with ALL in first CR.
The incidence of moderate to severe acute GVHD was quite low, especially for those patients who were treated prophylactically with the three-drug regimen of cyclosporine, methotrexate, and p r e d n i~o n e .~~ Unfortunately, the incidence of chronic GVHD and death from complications associated with GVHD are still major problems to overcome.
Since we instituted our policy of preemptive treatment with DHPG (gancyclovir) for patients at high risk for the development of CMV-IP,52 the incidence of fatal CMV-IP has decreased significantly. In this group of 99 patients, only 3% of patients died directly from CMV-IP. However, it should be noted that although only I of the 34 patients with ALL died directly from CMV-IP, 6 of these 34 patients (18%) developed CMV-IP, and the OS and DFS for these 6 patients was significantly worse compared with the 28 patients who did not develop CMV-IP (P = .03 for OS and P = .O 1 for DFS). For the 7 of 6 1 (1 1 %) of patients with AML who developed CMV-IP, their probabilities of OS and DFS were not significantly affected.
This study was not designed to compare the efficacy of the FTBI/VP-I6 regimen with the more traditional regimen of FTBI/high-dose cyclophosphamide (CY). We previously reported our results using FTBI/CY to prepare a group of patients with acute leukemia in first CR for BMT with similar demographics and disease characteristics as the patients in this
In that report, the probability of DFS for the 23 patients with ALL was 74%. with a relapse rate of 19%, and for the 25 patients with AML, the rates were 50% and 17%, respectively. We are now starting a phase I11 trial in which patients with AML in first CR or chronic myelogenous leukemia in chronic phase will be randomized to receive either FTBI/CY or FTBI/VP-I6 as the preparative regimen for allogeneic BMT. The results of that study should establish whether there is any advantage to R B I / VP-16 over FTBI/CY for this group of patients.
